Enanta Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 26, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Market Cap	400	256	220	235	1,078	1,150
Market Cap Growth	146.81%	16.59%	-6.66%	-78.19%	-6.20%	25.09%
Enterprise Value	359.43	125.04	26.85	-108.17	854.46	911.05
Last Close Price	13.75	11.97	10.36	11.17	51.87	56.81
PS Ratio	5.78	3.92	3.25	2.97	12.52	11.84
PB Ratio	3.35	3.96	1.70	1.09	3.36	2.88
P/TBV Ratio	2.97	3.95	1.70	1.08	3.33	2.87
EV/Sales Ratio	5.19	1.91	0.40	-1.37	9.92	9.39
EV/EBITDA Ratio	-	-	-	0.80	-	-
EV/EBIT Ratio	-	-	-	0.79	-	-
EV/FCF Ratio	-	-	-	0.96	-	-
Debt / Equity Ratio	0.45	0.85	0.42	0.10	0.07	0.00
Net Debt / Equity Ratio	-0.92	-2.02	-1.50	-1.58	-0.70	-0.60
Net Debt / EBITDA Ratio	1.93	1.62	1.62	2.55	1.85	2.25
Net Debt / FCF Ratio	11.16	4.07	1.99	3.06	2.58	3.37
Asset Turnover	0.21	0.20	0.16	0.19	0.21	0.21
Quick Ratio	3.69	4.03	4.43	6.03	9.04	7.40
Current Ratio	3.84	4.21	5.20	6.73	10.45	8.82
Return on Equity (ROE)	-50.98%	-84.63%	-67.17%	-49.74%	-33.78%	-18.48%
Return on Assets (ROA)	-18.77%	-25.47%	-28.60%	-33.46%	-30.31%	-17.40%
Return on Invested Capital (ROIC)	-35.83%	-75.01%	-124.48%	-156.54%	-94.18%	-66.38%
Return on Capital Employed (ROCE)	-21.84%	-30.99%	-33.89%	-36.83%	-33.10%	-25.35%
Buyback Yield / Dilution	-18.33%	-0.85%	-0.90%	-1.78%	-2.14%	-1.16%
Total Shareholder Return	-18.33%	-0.85%	-0.90%	-1.78%	-2.14%	-1.16%

SEC Filings: 10-K · 10-Q